Oxerutins are a group of chemicals derived from a naturally occurring bioflavonoid called rutin.
This supplement has been widely used in Europe since the mid-1960s, as a treatment for conditions in which blood or lymph vessels leak fluid. Considerable evidence suggests that oxerutins are effective. Unfortunately, it is difficult to find this supplement in North America.
Although they are closely related to a natural flavonoid, oxerutins are not found in food. The only way to take them is in a supplement.
For varicose veins/venous insufficiency , oxerutins are usually taken in dosages ranging from 900 mg to 1,200 mg daily. A typical schedule is 1,000 mg daily, taken in two separate doses of 500 mg.
One particular oxerutin called troxerutin may be taken alone (in similar dosages) as a treatment for varicose veins. There is no evidence as yet that rutin itself is effective.
Varicose means enlarged or distended. A varicose vein is abnormally enlarged, allowing blood to pool and stagnate instead of moving it efficiently toward the heart. Surface veins of the leg are those most vulnerable to becoming varicose. Venous insufficiency is a closely related condition affecting larger veins deep within the leg. In either case, blood pools within the vein and exerts pressure against the vein walls and capillaries, resulting in pain, aching, swelling, and feelings of heaviness and fatigue. In addition, varicose veins present a cosmetic problem: bulging, often ropy, blue or purple lines visible on the skin of the lower legs.
What Is the Scientific Evidence for Oxerutins?
Varicose Veins/Venous Insufficiency
About 20 double-blind, placebo-controlled studies, enrolling a total of more than 2,000 participants, have examined oxerutins' effectiveness for treating varicose veins and venous insufficiency. Virtually all found oxerutins significantly more effective than placebo, giving substantial relief from swelling, aching, leg pains, and other uncomfortable symptoms, while causing no significant side effects.
Those who took oxerutins had significantly less lower-leg edema than the placebo group. Furthermore, these results lasted through a 6-week follow-up period, even though participants were no longer taking oxerutins. Compression stockings, on the other hand, produced no lasting benefit after participants stopped wearing them. They gave symptomatic relief while they were worn, but they didn't improve capillary circulation in a lasting way, as oxerutins apparently did.
Regarding aching, sensations of heaviness, and other uncomfortable symptoms, however, there was little difference between the two groups. The authors theorized that the compression stockings gave both groups so much symptomatic relief that it was difficult to demonstrate a separate subjective benefit of oxerutin therapy.
In all of these studies, the dosage used was 3 g daily—about 3 times the typical dosage for venous insufficiency.
Oxerutins have been given to pregnant women in some studies, with no apparent harmful effects. However, their safety for pregnant or nursing women cannot be regarded as absolutely proven. In addition, the safety of oxerutins has not been established for people with severe liver or kidney disease.
- Reviewer: EBSCO CAM Review Board
- Review Date: 09/2014 -
- Update Date: 09/18/2014 -